Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

AIM WINNERS & LOSERS: Hutchmed notes phase 2 trial; Tricorn drops 25%

Wed, 28th Jul 2021 10:58

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Hutchmed (China) Ltd, up 9.0% at 585.08 pence, 12-month range 337.00p-656.00p. Alongside AstraZeneca PLC, the Hong Kong-based pharmaceutical company kicks off a phase 2 trial of Orpathys in some cancer patients. A first patient was dosed on Tuesday. The trial will probe the effectiveness of Orpathys in sufferers of advanced or metastatic MET amplified gastric cancer, - cancer formed in the lining of the stomach - or adenocarcinoma of the gastroesophageal junction, cancer of the oesophagus which connects a body's mouth to the stomach. Metastatic cancer refers to when the disease spreads to other parts of the body.

----------

Staffline PLC, up 9.1% at 63.50p, 12-month range 23.24p-82.38p. The recruitment and training firm rises in a positive read-across from mid-cap peer FDM Group Holdings PLC. FDM's pretax profit for the six months to June 30 falls 3.3% to GBP20.5 million from GBP21.2 million. The London-based firm posted revenue of GBP131.3 million, down 6.5% from GBP140.5 million. However, recruitment and training levels ramped up significantly in the first half to meet growing client demand, FDM says. Its stock was 3.0%.

----------

Empire Metals Ltd, up 7.8% at 2.59 p, 12-month range 1.70p-5.73p. The resource exploration and development company says the third phase of reverse circulation drilling of Eclipse gold project in Australia shows "encouraging results". Drilling confirms the existence of "additional mineralised zones".

----------

AIM - LOSERS

----------

Tricorn Group PLC, down 25% at 3.77p, 12-month range 3.16p-9.00p. The Worcestershire-based tube parts manufacturer hits this 12-month low on Wednesday as it warns that, while it is working within its lending facilities, it may soon need to operate outside of them as cost pressures ramp up. Tricorn notes global supply chain disruption as well as pressure on operating costs, margins and working capital. What's more, some overdue debts from customers are still outstanding. "Whilst the group's principal lending bank is expected to remain supportive, certain restrictions on these facilities are being imposed," Tricorn cautions, adding that these curbs will be eased in the event of an injection of funds.

----------

Total Produce PLC, down 16% at 177.92p, 12-month range 85.75p-235.00p. The fresh produce firm says the initial public offering price for joint venture company Dole PLC has been cut to between USD16 and USD17 per share from USD20 to USD23 previously. Total Produce says its shareholders will own just over 57% of Dole post-IPO, down from just shy of 62%.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
Today 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

Today 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...

29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while a...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.